Bank of New York Mellon Corp Acquires Shares of 161,767 Capricor Therapeutics, Inc. $CAPR

Key Points

• Bank of New York Mellon acquired 161,767 Capricor Therapeutics shares worth approximately $3.9 million, giving it a 0.28% stake. Several other institutional investors also recently initiated positions, with institutions collectively owning 21.68% of CAPR.
• Capricor faces uncertainty after the FDA extended its review of deramiocel, while securities class-action litigation alleges misleading statements related to clinical data. These developments may delay regulatory catalysts and increase legal and disclosure risks.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $29.15; CAPR opened at $9.40, well below its 52-week high of $40.37. The company also reported a quarterly loss of $0.70 per share, missing estimates.

Bank of New York Mellon Corp bought a new position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 161,767 shares of the biotechnology company's stock, valued at approximately $3,895,000. Bank of New York Mellon Corp owned about 0.28% of Capricor Therapeutics at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Suvretta Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $51,533,000. Tang Capital Management LLC bought a new position in Capricor Therapeutics in the fourth quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new position in Capricor Therapeutics during the fourth quarter worth about $43,516,000. Darwin Global Management Ltd. acquired a new position in Capricor Therapeutics during the fourth quarter worth about $23,168,000. Finally, SB Capital Management Inc acquired a new position in Capricor Therapeutics during the fourth quarter worth about $11,544,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Negative Sentiment: An analyst reportedly downgraded Capricor to “Hold,” citing the FDA’s extension of the review period for deramiocel and changes related to the Duchenne muscular dystrophy program. The delay pushes out a potential regulatory catalyst and may increase uncertainty surrounding the therapy’s approval timeline. Capricor Downgrade to Hold on Deramiocel PDUFA Extension and DMD Change
• Negative Sentiment: Multiple law firms publicized an existing securities class action against Capricor Therapeutics, alleging violations of federal securities laws and misstatements related to clinical data, including the HOPE-3 trial. The alleged class period runs from December 17, 2025, through July 26, 2026, with September 28, 2026, set as the deadline for investors to seek lead-plaintiff status. These announcements do not represent separate confirmed findings, but they highlight potential litigation costs, reputational damage and disclosure risk for CAPR. Rosen Capricor Securities Class Action Deadline
• Neutral Sentiment: The numerous September 3–4 investor notices largely repeat the same class-action deadline and encourage affected shareholders to contact plaintiffs’ firms. They provide little new information about Capricor’s operating performance or deramiocel’s clinical prospects, so the immediate stock impact is likely driven more by the FDA review delay and litigation overhang than by the notices themselves. Kaplan Fox Capricor Investor Notice

Insiders Place Their Bets

In related news, CFO Anthony Bergmann sold 24,100 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 25,000 shares of company stock valued at $759,158 in the last three months. Corporate insiders own 9.20% of the company's stock.

Wall Street Analyst Weigh In

CAPR has been the subject of a number of research analyst reports. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Friday, August 14th. B. Riley Financial lowered shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $10.00 target price on the stock. in a research report on Monday, July 27th. LADENBURG THALM/SH SH cut shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, July 30th. JonesTrading downgraded shares of Capricor Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, July 31st. Finally, Oppenheimer upgraded Capricor Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Tuesday, August 25th. Three investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $29.15.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $9.40 on Friday. The company has a 50 day simple moving average of $12.52 and a 200 day simple moving average of $23.80. Capricor Therapeutics, Inc. has a 1 year low of $2.96 and a 1 year high of $40.37. The firm has a market cap of $546.52 million, a PE ratio of -3.84 and a beta of 0.72.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.11). As a group, research analysts anticipate that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.